T&R Biofab Co., Ltd. (KOSDAQ:246710)
South Korea · Delayed Price · Currency is KRW 2,230.00
-45.00 (-1.98%)
Sep 21, 2026, 3:30 PM KST
T&R Biofab Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Operating Revenue | 32,732 | 26,967 | 4,874 | 5,199 |
Other Revenue | - | - | - | -0 |
| 32,732 | 26,967 | 4,874 | 5,199 | |
Revenue Growth | 120.91% | 453.32% | -6.26% | - |
Cost of Revenue | 22,535 | 20,139 | 2,766 | 4,151 |
Gross Profit | 10,198 | 6,828 | 2,108 | 1,048 |
Selling, General & Admin | 9,391 | 9,367 | 7,230 | 7,024 |
Research & Development | 3,905 | 4,524 | 5,510 | 4,399 |
Amortization of Goodwill & Intangibles | 257.24 | 265.87 | 83.77 | 61.8 |
Other Operating Expenses | 262.03 | 285.72 | 172.15 | 227.69 |
Operating Expenses | 15,453 | 15,496 | 15,407 | 13,902 |
Operating Income | -5,255 | -8,668 | -13,299 | -12,853 |
Interest Expense | -4,897 | -6,083 | -3,071 | -3.24 |
Interest & Investment Income | 153.26 | 281.18 | 1,227 | 1,676 |
Currency Exchange Gain (Loss) | 250.91 | -32.59 | 7.49 | 0.97 |
Other Non Operating Income (Expenses) | -16,319 | -16,843 | 11,112 | -1,424 |
EBT Excluding Unusual Items | -26,067 | -31,346 | -4,023 | -12,604 |
Gain (Loss) on Sale of Investments | -2,044 | 1,474 | -517.37 | 5.26 |
Gain (Loss) on Sale of Assets | 86.26 | 72.86 | -5.8 | -0.14 |
Asset Writedown | - | - | - | -195.49 |
Other Unusual Items | 312.66 | -2,152 | -3,133 | -625.01 |
Pretax Income | -27,712 | -31,951 | -7,679 | -13,419 |
Net Income | -27,712 | -31,951 | -7,679 | -13,419 |
Net Income to Common | -27,712 | -31,951 | -7,679 | -13,419 |
Net Income Growth | - | - | - | - |
Shares Outstanding (Basic) | 45 | 32 | 26 | 25 |
Shares Outstanding (Diluted) | 45 | 32 | 26 | 25 |
Shares Change | 90.06% | 23.66% | 1.61% | - |
EPS (Basic) | -614.92 | -999.32 | -297.00 | -527.37 |
EPS (Diluted) | -614.92 | -999.32 | -297.00 | -527.37 |
EPS Growth | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Free Cash Flow | -4,552 | -9,612 | -14,309 | -19,456 |
Free Cash Flow Per Share | -101.01 | -300.63 | -553.45 | -764.65 |
Gross Margin | 31.16% | 25.32% | 43.24% | 20.16% |
Operating Margin | -16.05% | -32.14% | -272.87% | -247.22% |
Profit Margin | -84.66% | -118.48% | -157.56% | -258.10% |
Free Cash Flow Margin | -13.91% | -35.64% | -293.60% | -374.22% |
EBITDA | -358.15 | -3,635 | -10,895 | -10,697 |
EBITDA Margin | -1.09% | -13.48% | -223.55% | -205.74% |
D&A For EBITDA | 4,897 | 5,034 | 2,404 | 2,156 |
EBIT | -5,255 | -8,668 | -13,299 | -12,853 |
EBIT Margin | -16.05% | -32.14% | -272.87% | -247.22% |
Advertising Expenses | - | 375.67 | 390.07 | 267.47 |